EACTS 34th Annual Meeting
Learn more Register Now

Late Breaking Clinical Trials submission is now open.  Deadline for submission will be 16 August 2020 @ 23:59 GMT

Late breaking trials are typically first-time international presentations of the primary endpoint or important secondary endpoint results of prospective multi-centre randomized trials or presentations of large-scale, impactful single-center or multicenter registries, first-in-man experiences with novel devices or drugs, and important follow-up data from major randomized trials.


For all Abstracts which are accepted for presentation at the EACTS Annual Meeting, the full paper must then be submitted to the European Journal of Cardio-Thoracic Surgery or Interactive CardioVascular and Thoracic Surgery, before the meeting.

The audio-visual recording of the scientific presentations will be the property of the EACTS.


Please follow the instructions given on-line, otherwise your abstract cannot be selected for review. A summary of the guidelines is as follows:

The abstract language is English
Abstract – The template provided is the only format accepted – please see further instructions
There should be no more than 8 authors
Since the abstracts will be judged anonymously, the text may not reveal the institutional affiliation
Each abstract submitted to the Association for possible presentation at the EACTS Annual Meeting must summarize an original contribution and must not have been submitted, presented, published or accepted for presentation or publication elsewhere
Abstracts will not be accepted unless they are submitted according to the format and instructions described previously, and submitted using the online system no later than 16 August 2020.

EACTS Submission Conditions

For abstracts accepted from the Late Breaking Clinical Trial, submission of your full paper to EJCTS is optional, but will be welcomed.

The audio-visual recording of the scientific presentations will be the property of the EACTS.

Authors will be notified in writing by September 2020 if the EACTS Programme Committee has accepted their abstract(s).


The Editor requires authors to disclose any commercial associations that might pose a conflict of interest in connection with the submitted article.

All sources of funding for work should be acknowledged in the disclosure statement, as should all institutional affiliations of the authors (including corporate appointments). Other kinds of associations, such as consultancies, stock ownership or other equity interests or patent licensing arrangements should be disclosed. The Editor reserves the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above-mentioned requirements.